Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

3.02EUR
20 Apr 2018
Change (% chg)

€0.02 (+0.67%)
Prev Close
€3.00
Open
€3.04
Day's High
€3.04
Day's Low
€2.96
Volume
37,826
Avg. Vol
107,039
52-wk High
€3.79
52-wk Low
€2.40

Select another date:

Wed, Apr 18 2018

BRIEF-Transgene Says PCPV Most Promising Therapeutic Candidate Amongst Evaluated Poxviridae

* PCPV WAS FOUND TO BE MOST PROMISING THERAPEUTIC CANDIDATE AMONGST POXVIRIDAE EVALUATED BY TRANSGENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene To Announce Major Clinical Results In 2018

* TRANSGENE TO ANNOUNCE MAJOR CLINICAL RESULTS IN 2018 AND ACHIEVE PROMISING PROGRESS ON ITS NEW ONCOLYTIC VIRUSES

BRIEF-Transgene Says ‍First Patient Dosed In China In Trial Of T101​

* ‍FIRST CHRONIC HEPATITIS B PATIENT DOSED IN CHINA IN A PHASE 1 TRIAL OF T101​

BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​

* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE'S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​

BRIEF-Transgene Collaborates with BioInvent To Treat Solid Tumors

* BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS

BRIEF-Transgene successfully raises 14.4 million euros

* TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS

BRIEF-Transgene launches capital increase by accelerated book-build offering

* TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING

BRIEF-Transgene announces first patient has been treated in TG6002 trial

* ‍FIRST PATIENT TREATED IN A PHASE 1/2A TRIAL (ONCOVIRAC) OF NOVEL ONCOLYTIC VIRUS TG6002 IN RECURRENT GLIOBLASTOMA​

BRIEF-Transgene's TG1050 well tolerated and induces strong specific immune response

* TG1050 IS WELL TOLERATED AND INDUCES A STRONG SPECIFIC IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: